ClinicalTrials.gg
CompletedNCT01904279JIGSAW 117Updated Jun 14, 2017Results posted

A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA)

A Phase 1 interventional study of Tocilizumab in Juvenile Idiopathic Arthritis, sponsored by Hoffmann-La Roche. Completed at 35 sites in 12 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2017-06-14.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Non-randomized
Ages
1 Year to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing tocilizumab in Arthritis, Juvenile — 2 open to participants now, 2 under way, 1 of them phase 3. tocilizumab · Arthritis, Juvenile.

Enrollment
10th of 21
52 · median 52
Started
2013
with 4 others
Phase 1
4 of 21
none open now
Registered
15th of 21
by date
Lead sponsor
12 of 21
Hoffmann-La Roche

Among the 21 studies testing tocilizumab in Arthritis, Juvenile, this one is the 10th largest by enrollment, is one of 5 that started in 2013, is one of 4 in phase 1, and was the 15th registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

2 of the 21 studies testing tocilizumab in Arthritis, Juvenile are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.

This study: 1 Year to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing tocilizumab in Arthritis, Juvenile, or all of them as a file.
02

Study summary

This open-label, multicenter study evaluated the pharmacokinetics, pharmacodynamics and safety of SC administered TCZ in participants with pJIA.

03

Conditions studied

  • Juvenile Idiopathic Arthritis

Browse trials for

04

Who can participate

Ages eligible
1 Year to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ages 1 year (12 years for participants in Russia) up to and including 17 years at screening
  • Diagnosis of pJIA according to International League of Associations for Rheumatology classification
  • Rheumatoid factor (RF)-positive pJIA
  • RF-negative pJIA
  • Extended oligoarticular JIA with a polyarticular course
  • History of inadequate clinical response (in the opinion of the treating physician) to or inability to tolerate methotrexate (MTX)
  • Participants currently receiving TCZ by the intravenous (IV) route of administration and with well-controlled disease do not require a period of discontinuation of IV TCZ and should have their first dose of SC TCZ administered on the date that their next IV TCZ infusion would be due. Participants participating in the study may be either naive to TCZ therapy or may be switching from IV to SC. The total number of participants switching from IV TCZ must account for no more than 50 percent (%) of the total participant number. To account for the baseline TCZ concentrations in these participants, information on the last 4 IV TCZ infusions prior to baseline will be collected
  • Concurrent treatment with disease-modifying antirheumatic drugs (DMARDs) (including MTX), nonsteroidal anti-inflammatory drugs (NSAIDs), and oral are permitted at the discretion of the investigator
  • Females of and non-sterile males with female partner of childbearing potential must agree to use effective as defined by protocol

Exclusion criteria

Exclusion Criteria:

  • Prior discontinuation of IV TCZ because of inadequate clinical response or safety events (including )
  • Participants with poorly controlled disease (in the opinion of the treating physician) despite current treatment with IV TCZ
  • pJIA that is well controlled by any treatment agent other than TCZ (Juvenile Arthritis Disease Activity Score 71 [JADAS-71] less than or equal to (\< / =) 3.8)
  • Participants who are wheelchair-bound or bedridden
  • Any other auto-immune, rheumatic disease, or overlapping syndrome other than the permitted pcJIA subsets
  • Lack of recovery from recent surgery or an interval of \<6 weeks since surgery at the time of the screening visit
  • Females who are pregnant, lactating, or intending to become pregnant during study conduct
  • Any significant concurrent medical or surgical condition that would jeopardize the participant's safety or ability to complete the study
  • Known (HIV) infection or other acquired forms of immune compromise or inborn conditions characterized by a compromised immune system
  • History of alcohol, drug, or chemical abuse within 6 months of screening
  • Any active acute, subacute, chronic, or recurrent bacterial, viral, or systemic fungal infection or any major episode of infection requiring hospitalization or treatment during screening or treatment with IV antibiotics completed within 4 weeks of the screening visit or oral antibiotics completed within 2 weeks of the screening visit
  • History of atypical tuberculosis (TB) or active TB requiring treatment within 2 years prior to screening visit
  • Positive purified protein derivative (PPD) at screen, unless treated with anti-TB therapy for at least 4 weeks prior to receiving study drug and chest radiograph is negative for active TB within 6 months of screening visit according to local practice
  • History of reactivation or new onset of a systemic infection such as herpes zoster or Epstein-Barr virus within 2 months of the screening visit
  • surface antigen or antibody positivity or chronic viral or hepatitis
  • History of concurrent serious gastrointestinal disorders such as ulcer or inflammatory bowel disease, Crohn's disease, ulcerative colitis, or other symptomatic lower gastrointestinal conditions
  • History of or current cancer or lymphoma
  • Uncontrolled diabetes mellitus with elevated glycosylated
  • Active uveitis at screening
  • Inadequate hematologic, renal or liver function
  • Prior stem cell transplant at any time
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    TCZ SC 162 mg Q3W

    Participants with body weight less than (\<) 30 kilograms (kg) will be administered 162 milligrams (mg) of TCZ as a SC injection every 3 weeks (Q3W) for 52 weeks.

    Drug: Tocilizumab

  • Experimental
    TCZ SC 162 mg Q2W

    Participants with body weight greater than or equal to (\>/=) 30 kg will be administered 162 mg of TCZ as a SC injection every 2 weeks (Q2W) for 52 weeks.

    Drug: Tocilizumab

Interventions

  • Participants will receive 162 mg of TCZ as SC injection Q3W or Q2W for 52 weeks

    Also known as: RoActemra/Actemra

06

What researchers measure

Primary outcomes

  1. Minimum Serum Concentration (Cmin) of TCZ at Steady State

    Detailed timeframe for TCZ SC 162 mg Q3W arm: pre-dose (Hour 0), 96, 504, 1008, 2016, 2022, 2064, 2112, 2160, 2520 hours post Day 1 dose (additionally at 6, 12, 48, 120, 2028 hours post Day 1 dose in participants \>/=2 years old). Detailed timeframe for TCZ SC 162 mg Q2W arm: pre-dose (Hour 0), 6, 12, 48, 120, 336, 672, 1008, 2016, 2022, 2028, 2040, 2064, 2112, 2160, 2520 hours post Day 1 dose.

    Time frame: Pre-dose (Hour 0) up to 2520 hours post Day 1 dose (detailed timeframe is provided in outcome description section)

  2. Area Under the Curve at Steady-state Over a 12-week Interval (AUC12weeks) of TCZ Treatment

    Detailed timeframe for TCZ SC 162 mg Q3W arm: pre-dose (Hour 0), 96, 504, 1008, 2016 hours post Day 1 dose (additionally at 6, 12, 48, 120 hours post Day 1 dose in participants \>/=2 years old). Detailed timeframe for TCZ SC 162 mg Q2W arm: pre-dose (Hour 0), 6, 12, 48, 120, 336, 672, 1008, 2016 post Day 1 dose.

    Time frame: Pre-dose (Hour 0) up to 2016 hours post Day 1 dose (detailed timeframe is provided in outcome description section)

  3. Maximum Serum Concentration (Cmax) of TCZ at Steady State

    Detailed timeframe for TCZ SC 162 mg Q3W arm: pre-dose (Hour 0), 96, 504, 1008, 2016, 2022, 2064, 2112, ,2160, 2520 hours post Day 1 dose (additionally at 6, 12, 48, 120, 2028 hours post Day 1 dose in participants \>/=2 years old). Detailed timeframe for TCZ SC 162 mg Q2W arm: pre-dose (Hour 0), 6, 12, 48, 120, 336, 672, 1008, 2016, 2022, 2028, 2040, 2064, 2112, 2160, 2520 hours post Day 1 dose.

    Time frame: Pre-dose (Hour 0) up to 2520 hours post Day 1 dose (detailed timeframe is provided in outcome description section)

Secondary outcomes

  1. Change From Baseline in Serum Interleukin-6 (IL-6) Levels

    IL-6 is a cytokine associated with disease activity in juvenile idiopathic arthritis (JIA) including the polyarticular juvenile idiopathic arthritis (pJIA) subset. It is found in high levels in the synovial fluid and is associated with indicators of inflammatory activity.

    Time frame: Baseline, Days 0.25, 0.5, 2, 4, 5, 84.25, 84.5, 85, 86, 88, 90; Weeks 2, 3, 4, 6, 12, 14, 15, 27, 28, 36, 44, 52

  2. Change From Baseline in Soluble IL-6 Receptor Levels

    Time frame: Baseline, Days 0.25, 0.5, 2, 4, 5, 84.25, 84.5, 85, 86, 88, 90; Weeks 2, 3, 4, 6, 12, 14, 15, 27, 28, 36, 44, 52

  3. Change From Baseline in C-Reactive Protein (CRP) Levels

    Time frame: Baseline, Weeks 4, 6, 9, 12,18, 20, 27, 28, 36, 44, 45, 51, 52

  4. Change From Baseline in Erythrocyte Sedimentation Rate (ESR)

    The ESR is an acute phase reactant and a measure of inflammation. A negative change from baseline indicates improvement.

    Time frame: Baseline, Week 4, 6, 9, 12, 18, 20, 27, 28, 36, 44, 45, 51, 52

  5. Percentage of Participants With Anti-TCZ Antibodies of Neutralizing Potential

    Time frame: Baseline up to Week 52

07

Results

Posted Mar 16, 2017

Participant flow

A total of 52 participants were enrolled in the study. Study included a 21-day screening period.

Participant flow — Overall Study
MilestoneTCZ SC 162 mg Q3WTCZ SC 162 mg Q2W
Started2725
Completed2422
Not completed33
Withdrew: Lack of efficacy23
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryMinimum Serum Concentration (Cmin) of TCZ at Steady State

Detailed timeframe for TCZ SC 162 mg Q3W arm: pre-dose (Hour 0), 96, 504, 1008, 2016, 2022, 2064, 2112, 2160, 2520 hours post Day 1 dose (additionally at 6, 12, 48, 120, 2028 hours post Day 1 dose in participants \>/=2 years old). Detailed timeframe for TCZ SC 162 mg Q2W arm: pre-dose (Hour 0), 6, 12, 48, 120, 336, 672, 1008, 2016, 2022, 2028, 2040, 2064, 2112, 2160, 2520 hours post Day 1 dose.

Time frame:
Pre-dose (Hour 0) up to 2520 hours post Day 1 dose (detailed timeframe is provided in outcome description section)
Reported as:
Median · Micrograms/milliliter (mcg/mL)
Minimum Serum Concentration (Cmin) of TCZ at Steady State
Micrograms/milliliter (mcg/mL)TCZ SC 162 mg Q3WTCZ SC 162 mg Q2W
Minimum Serum Concentration (Cmin) of TCZ at Steady State13.35 (0.21 to 52.25)12.71 (0.19 to 23.75)
PrimaryArea Under the Curve at Steady-state Over a 12-week Interval (AUC12weeks) of TCZ Treatment

Detailed timeframe for TCZ SC 162 mg Q3W arm: pre-dose (Hour 0), 96, 504, 1008, 2016 hours post Day 1 dose (additionally at 6, 12, 48, 120 hours post Day 1 dose in participants \>/=2 years old). Detailed timeframe for TCZ SC 162 mg Q2W arm: pre-dose (Hour 0), 6, 12, 48, 120, 336, 672, 1008, 2016 post Day 1 dose.

Time frame:
Pre-dose (Hour 0) up to 2016 hours post Day 1 dose (detailed timeframe is provided in outcome description section)
Reported as:
Mean · mcg*day/mL
Area Under the Curve at Steady-state Over a 12-week Interval (AUC12weeks) of TCZ Treatment
mcg*day/mLTCZ SC 162 mg Q3WTCZ SC 162 mg Q2W
Area Under the Curve at Steady-state Over a 12-week Interval (AUC12weeks) of TCZ Treatment2998 (1465 to 7708)1933 (324 to 3098)
PrimaryMaximum Serum Concentration (Cmax) of TCZ at Steady State

Detailed timeframe for TCZ SC 162 mg Q3W arm: pre-dose (Hour 0), 96, 504, 1008, 2016, 2022, 2064, 2112, ,2160, 2520 hours post Day 1 dose (additionally at 6, 12, 48, 120, 2028 hours post Day 1 dose in participants \>/=2 years old). Detailed timeframe for TCZ SC 162 mg Q2W arm: pre-dose (Hour 0), 6, 12, 48, 120, 336, 672, 1008, 2016, 2022, 2028, 2040, 2064, 2112, 2160, 2520 hours post Day 1 dose.

Time frame:
Pre-dose (Hour 0) up to 2520 hours post Day 1 dose (detailed timeframe is provided in outcome description section)
Reported as:
Median · mcg/mL
Maximum Serum Concentration (Cmax) of TCZ at Steady State
mcg/mLTCZ SC 162 mg Q3WTCZ SC 162 mg Q2W
Maximum Serum Concentration (Cmax) of TCZ at Steady State62.44 (39.37 to 121.13)29.74 (7.56 to 50.3)
SecondaryChange From Baseline in Serum Interleukin-6 (IL-6) Levels

IL-6 is a cytokine associated with disease activity in juvenile idiopathic arthritis (JIA) including the polyarticular juvenile idiopathic arthritis (pJIA) subset. It is found in high levels in the synovial fluid and is associated with indicators of inflammatory activity.

Time frame:
Baseline, Days 0.25, 0.5, 2, 4, 5, 84.25, 84.5, 85, 86, 88, 90; Weeks 2, 3, 4, 6, 12, 14, 15, 27, 28, 36, 44, 52
Reported as:
Mean · picograms/milliliter (pg/mL)
Change From Baseline in Serum Interleukin-6 (IL-6) Levels
picograms/milliliter (pg/mL)TCZ SC 162 mg Q3WTCZ SC 162 mg Q2W
Baseline77.569 ± 278.37610.567 ± 11.24
Day 0.25-15.309 ± 108.1574.575 ± 7.555
Day 0.5-16.181 ± 116.58711.932 ± 13.33
Day 217.998 ± 157.29523.223 ± 23.935
Day 517.265 ± 186.21235.263 ± 64.907
Week 2—21.751 ± 49.964
Week 3-12.801 ± 198.038—
Week 4—15.944 ± 26.322
Week 6-0.412 ± 271.40917.841 ± 34.515
Week 12-45.569 ± 294.16917.236 ± 28.727
Day 84.2532.644 ± 65.09414.66 ± 24.026
Day 84.5-46.575 ± 318.21724.478 ± 31.747
Day 85—27.934 ± 53.23
Day 86-53.35 ± 285.83136.06 ± 82.547
Day 88-42.836 ± 280.04119.397 ± 22.712
Day 90-51.899 ± 299.5920.642 ± 20.247
Week 14—11.958 ± 16.665
Week 15-21.565 ± 312.758122.88
Week 27-16.408 ± 293.156—
Week 28—14.206 ± 20.762
Week 36-38.921 ± 303.85113.273 ± 24.814
Week 44—14.765 ± 18.458
Week 52-44.611 ± 289.69810.401 ± 18.455
SecondaryChange From Baseline in Soluble IL-6 Receptor Levels
Time frame:
Baseline, Days 0.25, 0.5, 2, 4, 5, 84.25, 84.5, 85, 86, 88, 90; Weeks 2, 3, 4, 6, 12, 14, 15, 27, 28, 36, 44, 52
Reported as:
Mean · nanograms per milliliter (ng/mL)
Change From Baseline in Soluble IL-6 Receptor Levels
nanograms per milliliter (ng/mL)TCZ SC 162 mg Q3WTCZ SC 162 mg Q2W
Baseline140.4 ± 225.72206.7 ± 241.69
Day 0.25-4.04 ± 41.141.78 ± 29.68
Day 0.5-1.45 ± 53.394.58 ± 51.71
Day 289.72 ± 75.2968.90 ± 66.75
Day 4323.4 ± NA—
Day 5194.46 ± 143.28124.65 ± 100.58
Week 2—193.25 ± 158.69
Week 3418.54 ± 237.02—
Week 4—239.86 ± 194.47
Week 6407.36 ± 344.44233.82 ± 234.92
Week 12464.77 ± 317.77286.06 ± 260.33
Day 84.25461.85 ± 280.99245.05 ± 253.45
Day 84.5482.55 ± 299.43274.85 ± 230.86
Day 85—268.72 ± 254.46
Day 86461.19 ± 345.97244.53 ± 257.08
Day 88514.89 ± 303.29256.47 ± 234.7
Day 90494.05 ± 276.35292.29 ± 229.2
Week 14—272.93 ± 241.9
Week 15497.21 ± 295.29200 ± NA
Week 27532.81 ± 270.07—
Week 28—295.28 ± 286.78
Week 36416.02 ± 305.07269.32 ± 276.03
Week 44—243.93 ± 299.72
Week 52470.6 ± 263.38209.51 ± 318.38
SecondaryChange From Baseline in C-Reactive Protein (CRP) Levels
Time frame:
Baseline, Weeks 4, 6, 9, 12,18, 20, 27, 28, 36, 44, 45, 51, 52
Reported as:
Mean · mg/L
Change From Baseline in C-Reactive Protein (CRP) Levels
mg/LTCZ SC 162 mg Q3WTCZ SC 162 mg Q2W
Baseline3.391 ± 5.273.356 ± 6.908
Week 4—-2.187 ± 5.270
Week 6-3 ± 5.21-2.368 ± 5.735
Week 9-3.069 ± 5.346—
Week 12-3.16 ± 5.285-1.783 ± 4.559
Week 18-3.213 ± 5.377—
Week 20—-1.336 ± 6.158
Week 27-3.122 ± 5.279—
Week 28—-2.467 ± 6.455
Week 36-3.254 ± 5.492-2.209 ± 5.316
Week 44—-2.039 ± 5.47
Week 45-3.153 ± 5.385—
Week 51-3.344 ± 5.453—
Week 52—-2.225 ± 5.285
SecondaryChange From Baseline in Erythrocyte Sedimentation Rate (ESR)

The ESR is an acute phase reactant and a measure of inflammation. A negative change from baseline indicates improvement.

Time frame:
Baseline, Week 4, 6, 9, 12, 18, 20, 27, 28, 36, 44, 45, 51, 52
Reported as:
Mean · millimeters per hour (mm/h)
Change From Baseline in Erythrocyte Sedimentation Rate (ESR)
millimeters per hour (mm/h)TCZ SC 162 mg Q3WTCZ SC 162 mg Q2W
Baseline15.9 ± 14.213 ± 13.1
Week 4—-7.0 ± 9
Week 6-10.6 ± 12.8-7.2 ± 10.5
Week 9-9.9 ± 10.9—
Week 12-9.8 ± 12.4-6.8 ± 13
Week 18-11.8 ± 12.3—
Week 20—-7.9 ± 11.2
Week 27-11.9 ± 12.2—
Week 28—-8 ± 14.2
Week 36-11.8 ± 12.8-8 ± 13.1
Week 44—-10.2 ± 13
Week 45-12 ± 12.2—
Week 51-12.2 ± 13—
Week 52—-8.5 ± 13.2
SecondaryPercentage of Participants With Anti-TCZ Antibodies of Neutralizing Potential
Time frame:
Baseline up to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Anti-TCZ Antibodies of Neutralizing Potential
percentage of participantsTCZ SC 162 mg Q3WTCZ SC 162 mg Q2W
Percentage of Participants With Anti-TCZ Antibodies of Neutralizing Potential3.78.0

Adverse events

Collected over Baseline up to Week 56. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TCZ SC 162 mg Q3W—1/27 (3.7%)23/27 (85.2%)
TCZ SC 162 mg Q2W—2/25 (8%)22/25 (88%)
Most frequent serious events
Most frequent serious events
EventTCZ SC 162 mg Q3WTCZ SC 162 mg Q2W
ArthralgiaMusculoskeletal and connective tissue disorders0/271/25
Decreased appetiteMetabolism and nutrition disorders0/271/25
Croup infectiousInfections and infestations1/270/25
VaricellaInfections and infestations1/270/25
Most frequent other events
Showing 10 of 45
Most frequent other events
EventTCZ SC 162 mg Q3WTCZ SC 162 mg Q2W
NasophryngitisInfections and infestations11/277/25
CoughRespiratory, thoracic and mediastinal disorders10/273/25
Injection Site ErythemaGeneral disorders4/276/25
HeadacheNervous system disorders1/276/25
NauseaGastrointestinal disorders1/275/25
VomitingGastrointestinal disorders4/275/25
ArthralgiaMusculoskeletal and connective tissue disorders5/274/25
DiarrhoeaGastrointestinal disorders1/274/25
PyrexiaGeneral disorders2/274/25
Upper Respiratory Tract InfectionInfections and infestations1/274/25

Baseline characteristics

Safety population included all participants who received at least one dose of treatment and who had at least one post-dose safety assessment.

Age, Continuous
Age, Continuous(years)TCZ SC 162 mg Q3WTCZ SC 162 mg Q2WTotal
Mean5.5 ± 2.113.9 ± 2.79.6 ± 4.9
Sex: Female, Male
Sex: Female, Male(Participants)TCZ SC 162 mg Q3WTCZ SC 162 mg Q2WTotal
Female181836
Male9716
08

Study locations

35 sites
  • Hartford, Connecticut 06106, United States
  • Chicago, Illinois 60611, United States
  • Chicago, Illinois 60637, United States
  • Hackensack, New Jersey 07601, United States
  • Charlotte, North Carolina 28203, United States
  • Durham, North Carolina 27710, United States
  • Cincinnati, Ohio 45229-3039, United States
  • Tulsa, Oklahoma 74135, United States
  • Salt Lake City, Utah 84109, United States
  • Seattle, Washington 98105, United States
  • Buenos Aires, 1270, Argentina
  • Westmead, New South Wales 2145, Australia
  • Parkville, Victoria 3052, Australia
  • Rio de Janeiro, RJ 20551-030, Brazil
  • Rio de Janeiro, RJ 21941-912, Brazil
  • Sao Paulo, SP 05403-000, Brazil
  • Sao Paulo, SP 22793-080, Brazil
  • Calgary, Alberta T3B 6A8, Canada
  • Ottawa, Ontario K1H 8L1, Canada
  • Toronto, Ontario M5G 1X8, Canada
  • Le Kremlin Bicêtre, 94275, France
  • Berlin, 13353, Germany
  • Freiburg, 79106, Germany
  • Sankt Augustin, 53757, Germany
  • Roma, Lazio 00165, Italy
  • Genova, Liguria 16147, Italy
  • Firenze, Toscana 50139, Italy
  • Monterrey, 64460, Mexico
  • Moscow, 115522, Russian Federation
  • Moscow, 119991, Russian Federation
  • Esplugas de Llobregat, Barcelona 08950, Spain
  • Madrid, 28034, Spain
  • Madrid, 28046, Spain
  • Bristol, BS2 8BJ, United Kingdom
  • Liverpool, L12 2AP, United Kingdom
09

References and documents

Publications

  • Ruperto N, Brunner HI, Ramanan AV, Horneff G, Cuttica R, Henrickson M, Anton J, Boteanu AL, Penades IC, Minden K, Schmeling H, Hufnagel M, Weiss JE, Pardeo M, Nanda K, Roth J, Rubio-Perez N, Hsu JC, Wimalasundera S, Wells C, Bharucha K, Douglass W, Bao M, Mallalieu NL, Martini A, Lovell D, Benedetti F; Paediatric Rheumatology INternational Trials Organisation (PRINTO) and the Paediatric Rheumatology Collaborative Study Group (PRCSG). Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis. Rheumatology (Oxford). 2021 Oct 2;60(10):4568-4580. doi: 10.1093/rheumatology/keab047. PubMed 33506875 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2013, a primary completion of May 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2013
First posted
Jul 22, 2013
Start
Jul 2013
Primary completionActual
May 2016
CompletionActual
May 2016
Results first posted
Mar 16, 2017
Last update
Jun 14, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01904279
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 22, 2013
Start date
Jul 2013
Primary completion
May 2016
Completion
May 2016
Results posted
Mar 16, 2017
Last update
Jun 14, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion